Journal article
A Steady-State Evaluation of the Effects of Propantheline Bromide and Cholestyramine on the Bioavailability of Digoxin When Administered as Tablets or Capsules
Journal of clinical pharmacology, Vol.25(5), pp.360-364
07/08/1985
DOI: 10.1002/j.1552-4604.1985.tb02855.x
PMID: 4031112
Abstract
Drug interactions can profoundly alter the absorption of digoxin in tablet form. This study evaluated whether digoxin solution in capsules, a new dosage form with 90% to 100% bioavailability, would reduce such alterations, specifically those caused by cholestyramine and propantheline bromide. The investigation used a six-treatment, steady-state, balanced, incomplete block design with 18 healthy adults studied for four continuous two-week treatment periods. Treatments were either two 0.25 mg digoxin tablets or two 0.20 mg digoxin capsules administered alone, with propantheline, 15 mg qid, or with cholestyramine, 8 g qd. Bioavailability was determined from steady-state, 24-hour area under the serum concentration-time curve (AUC, ng × h/mL) and from 0- and 24-hour trough serum digoxin concentrations (ng/mL). The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 ± 13.3 (± SD), 22.4 ± 12.1, and 40.6 ± 13.9, respectively, while corresponding values for capsules were 31.7 ± 9.3, 24.7 ± 7.9, and 35.9 ± 12.8. The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 ± 0.47, 0.61 ± 0.38, and 1.09 ± 0.35, respectively; trough concentrations for capsules were 0.77 ± 0.28, 0.74 ± 0.28, and 0.96 ± 0.48, respectively. The only significant differences in AUC were seen when comparing tablets alone versus tablets with cholestyramine (P < .0005) and tablets with propantheline (P < .01). A significant finding was also observed when comparing trough concentrations for tablets alone versus tablets with cholestyramine (P < .005). The results confirm (1) bioequivalence of 0.20 mg capsules versus 0.25 mg tablets, (2) significant alterations in tablet bioavailability due to cholestyramine and propantheline, and (3) reduction of these alterations by the capsule dosage form. These findings suggest that digoxin capsules may offer clinical advantages over digoxin tablets in achieving predictable, consistent serum digoxin concentrations in patients receiving cholestyramine, propantheline, and similar drugs.
Details
- Title: Subtitle
- A Steady-State Evaluation of the Effects of Propantheline Bromide and Cholestyramine on the Bioavailability of Digoxin When Administered as Tablets or Capsules
- Creators
- Donald D Brown - Department of Internal Medicine, The University of Iowa Hospitals and Clinics, Iowa City, IowaJoanne Schmid - Department of Internal Medicine, The University of Iowa Hospitals and Clinics, Iowa City, IowaRobert A Long - Department of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, North CarolinaJ. Heyward Hull - Department of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, North Carolina
- Resource Type
- Journal article
- Publication Details
- Journal of clinical pharmacology, Vol.25(5), pp.360-364
- Publisher
- Blackwell Publishing Ltd
- DOI
- 10.1002/j.1552-4604.1985.tb02855.x
- PMID
- 4031112
- ISSN
- 0091-2700
- eISSN
- 1552-4604
- Number of pages
- 5
- Language
- English
- Date published
- 07/08/1985
- Academic Unit
- Cardiovascular Medicine; Internal Medicine
- Record Identifier
- 9984094511502771
Metrics
20 Record Views